About all

Lovenox Interactions: Uses, Dosage, Side Effects, Interactions, and Warnings

by alexxlab

What are the uses of Lovenox? What is the proper dosage of Lovenox? What are the potential side effects of Lovenox? How does Lovenox interact with other medications? What warnings are associated with Lovenox use?

Lovenox: Uses, Dosage, and Side Effects

Lovenox (enoxaparin) is an anticoagulant medication used to prevent and treat various blood clotting disorders. It is commonly prescribed to patients at risk of developing deep vein thrombosis (DVT) or pulmonary embolism (PE), particularly after surgery or during periods of prolonged immobilization. Lovenox works by inhibiting the formation of blood clots, reducing the risk of serious and potentially life-threatening complications.

Lovenox Dosage

The dosage of Lovenox varies depending on the specific condition being treated and the patient’s individual needs. Generally, the recommended dosage for DVT prevention is 40 mg once daily, while the dosage for treatment of DVT or PE is 1 mg per kilogram of body weight administered twice daily. Patients with certain medical conditions, such as renal impairment, may require a different dosage regimen. It is important to follow the healthcare provider’s instructions carefully and not exceed the recommended dosage.

Lovenox Side Effects

Like all medications, Lovenox can cause side effects. The most common side effects of Lovenox include:

  • Bleeding or bruising at the injection site
  • Nausea
  • Diarrhea
  • Headache
  • Fatigue

More serious side effects, though less common, may include severe bleeding, heparin-induced thrombocytopenia (a decrease in platelet count), and allergic reactions. Patients should report any unusual symptoms or side effects to their healthcare provider immediately.

Lovenox Interactions

Lovenox can interact with a variety of other medications, potentially increasing the risk of bleeding or other adverse effects. Some of the most common Lovenox interactions include:

  • Aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs)
  • Anticoagulants like warfarin (Coumadin)
  • Antidepressants like selective serotonin reuptake inhibitors (SSRIs)
  • Certain antibiotics, such as ciprofloxacin
  • Corticosteroids like prednisone

Patients should always inform their healthcare provider about all medications, supplements, and herbal remedies they are taking to ensure safe and appropriate use of Lovenox.

Lovenox Warnings and Precautions

Lovenox is generally well-tolerated, but there are some important warnings and precautions to consider:

  • Increased risk of bleeding, especially in patients with a history of bleeding disorders or recent surgery
  • Contraindicated in patients with active, uncontrolled bleeding
  • Caution in patients with renal impairment, as the drug is primarily eliminated through the kidneys
  • Increased risk of spinal or epidural hematoma in patients receiving neuraxial anesthesia or spinal puncture, which can lead to long-term or permanent paralysis
  • Potential for cross-reactivity and development of heparin-induced thrombocytopenia

Patients should discuss any concerns or pre-existing conditions with their healthcare provider before starting Lovenox treatment.

Lovenox and Alcohol/Food Interactions

There are a few known alcohol and food interactions with Lovenox:

  • Alcohol: Consuming alcohol while taking Lovenox may increase the risk of bleeding, as both substances can thin the blood.
  • Food: Lovenox can be taken with or without food, but the timing of administration should be consistent to maintain stable blood levels of the medication.

Patients should avoid excessive alcohol consumption and maintain a consistent dosing schedule when taking Lovenox.

Lovenox and Disease Interactions

Lovenox may interact with or be contraindicated in certain medical conditions, including:

  • Hemophilia or other bleeding disorders
  • Liver disease
  • Peptic ulcer disease
  • Retinopathy
  • Subacute bacterial endocarditis
  • Active bleeding
  • Hypertension
  • Renal dysfunction
  • Thrombocytopenia
  • Prematurity
  • Kidney disease

Patients with these or any other medical conditions should discuss the risks and benefits of Lovenox treatment with their healthcare provider.

Lovenox Interactions Checker – Drugs.com

Print

Save

There are 192 drugs known to interact with
Lovenox (enoxaparin), along with
12 disease interactions, and 2 alcohol/food interactions.

Of the total drug interactions,
94 are major, 92 are moderate, and 6 are minor.

Does Lovenox interact with my other drugs?

Enter other medications to view a detailed report.

  • View all 192 medications that may interact with Lovenox
  • View Lovenox alcohol/food interactions (2)
  • View Lovenox disease interactions (12)

Most frequently checked interactions

View interaction reports for Lovenox (enoxaparin) and the medicines listed below.

  • Major
  • Moderate
  • Minor
  • Unknown
  • albuterol
  • amlodipine
  • aspirin
  • Colace (docusate)
  • Coumadin (warfarin)
  • Fish Oil (omega-3 polyunsaturated fatty acids)
  • furosemide
  • gabapentin
  • hydrochlorothiazide
  • Lasix (furosemide)
  • levothyroxine
  • Lipitor (atorvastatin)
  • lisinopril
  • losartan
  • metformin
  • metoprolol
  • multivitamin
  • omeprazole
  • oxycodone
  • potassium chloride
  • prednisone
  • Protonix (pantoprazole)
  • simvastatin
  • Synthroid (levothyroxine)
  • tramadol
  • Tylenol (acetaminophen)
  • Vitamin C (ascorbic acid)
  • Vitamin D3 (cholecalciferol)
  • warfarin
  • Zofran (ondansetron)

Lovenox alcohol/food interactions

There are 2 alcohol/food interactions with Lovenox (enoxaparin).

Lovenox disease interactions

There are 12 disease interactions with Lovenox (enoxaparin) which include:

  • hemophilia
  • liver disease
  • peptic ulcer disease
  • retinopathy
  • subacute bacterial endocarditis
  • active bleeding
  • hypertension
  • renal dysfunction
  • thrombocytopenia
  • prematurity
  • hypertension
  • kidney disease

Report options

Loading…

QR code containing a link to this page

More about Lovenox (enoxaparin)

  • Lovenox consumer information
  • Compare alternatives
  • Pricing & coupons
  • Reviews (20)
  • Latest FDA alerts (5)
  • Side effects
  • Dosage information
  • During pregnancy
  • Generic availability
  • Support group
  • Drug class: heparins
  • Breastfeeding
  • En español

Related treatment guides

  • Acute Coronary Syndrome
  • Angina
  • Deep Vein Thrombosis
  • Deep Vein Thrombosis Prophylaxis after Abdominal Surgery

Drug Interaction Classification
These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
MajorHighly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
ModerateModerately clinically significant. Usually avoid combinations; use it only under special circumstances.
MinorMinimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
UnknownNo interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Lovenox HP Interactions Checker – Drugs.com

Print

Save

There are 192 drugs known to interact with
Lovenox HP (enoxaparin), along with
12 disease interactions, and 2 alcohol/food interactions.

Of the total drug interactions,
94 are major, 92 are moderate, and 6 are minor.

Does Lovenox HP interact with my other drugs?

Enter other medications to view a detailed report.

  • View all 192 medications that may interact with Lovenox HP
  • View Lovenox HP alcohol/food interactions (2)
  • View Lovenox HP disease interactions (12)

Most frequently checked interactions

View interaction reports for Lovenox HP (enoxaparin) and the medicines listed below.

  • Major
  • Moderate
  • Minor
  • Unknown
  • albuterol
  • amlodipine
  • amoxicillin
  • aspirin
  • atorvastatin
  • baclofen
  • Benadryl (diphenhydramine)
  • ciprofloxacin
  • Claritin (loratadine)
  • Colace (docusate)
  • Coumadin (warfarin)
  • Cymbalta (duloxetine)
  • dexamethasone
  • doxycycline
  • folic acid
  • gabapentin
  • ibuprofen
  • levothyroxine
  • Lipitor (atorvastatin)
  • lorazepam
  • losartan
  • Nexium (esomeprazole)
  • Norco (acetaminophen / hydrocodone)
  • prednisone
  • tramadol
  • Tylenol (acetaminophen)
  • Vitamin B12 (cyanocobalamin)
  • Vitamin C (ascorbic acid)
  • Vitamin D3 (cholecalciferol)
  • Xanax (alprazolam)

Lovenox HP alcohol/food interactions

There are 2 alcohol/food interactions with Lovenox HP (enoxaparin).

Lovenox HP disease interactions

There are 12 disease interactions with Lovenox HP (enoxaparin) which include:

  • hemophilia
  • liver disease
  • peptic ulcer disease
  • retinopathy
  • subacute bacterial endocarditis
  • active bleeding
  • hypertension
  • renal dysfunction
  • thrombocytopenia
  • prematurity
  • hypertension
  • kidney disease

Report options

Loading…

QR code containing a link to this page

More about Lovenox HP (enoxaparin)

  • Compare alternatives
  • Latest FDA alerts (5)
  • Side effects
  • Dosage information
  • During pregnancy
  • Drug class: heparins
  • Breastfeeding

Related treatment guides

  • Acute Coronary Syndrome
  • Angina
  • Deep Vein Thrombosis
  • Deep Vein Thrombosis Prophylaxis after Abdominal Surgery

Drug Interaction Classification
These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
MajorHighly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
ModerateModerately clinically significant. Usually avoid combinations; use it only under special circumstances.
MinorMinimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
UnknownNo interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

Lovenox Injectable – Product

Lovenox Injectable – Product – TabletWise.com

About us

  • 008
  • Terms of use

  • Overview
  • Benefits
  • Side effects
  • Precautions
  • Interactions
  • Contraindications

Overview

Lovenox Injectable / Lovenox Injectable is indicated for the treatment of deep vein thrombosis, Ischemic complications of unstable chest pain, Acute deep vein thrombosis, Non-q-wave myocardial infarction, Acute st-segment elevation myocardial infarction and other conditions .

Lovenox Injectable contains the following active ingredients: Enoxaparin Sodium. Available in injectable form.

Detailed information regarding the use, composition, dosage, side effects of Lovenox Injectable / Lovenox Injectable, as well as user reviews are provided below:

Uses

Lovenox Injectable is used for the treatment, control, prevention, & improvement of the following diseases, conditions and symptoms:

  • Deep vein thrombosis
  • Ischemic complications of unstable chest pain
  • Acute deep vein thrombosis 90 008
  • Numbers q -wave myocardial infarction
  • Acute st-segment height myocardial infarction

Learn more: Use

Side effects

The following is a list of possible side effects that may be caused by the ingredients of Lovenox Injectable. This list is not final. These side effects have been recorded previously, but are not always recorded when using the drug. Some of these side effects may be extremely rare, but have incredibly severe consequences. If you notice any side effects, contact your doctor immediately. Especially in the case of observing side effects for a long time.

  • Dyspnea
  • Hemorrhage
  • Irritation
  • Pain
  • Hematoma
  • Anemia
  • Ecchymosis

    • 900 06 Fever

  • Nausea
  • Dropsy
  • Dyspnea
  • Thrombocytopenia
  • Confusion
  • Diarrhea
  • Hematuria

    • 90 015

    If If you experience side effects not listed above, contact your healthcare provider for advice. In addition, you can report side effects to your local Food and Drug Administration.

    Precautions

    Before starting this drug, tell your doctor about any medications you are taking, nutritional supplements (such as vitamins, natural supplements, etc. ), allergies, existing medical conditions, and current health conditions (such as pregnancy, upcoming surgery, and etc.). The side effects of the drug may be more pronounced depending on the state of your body. Take this medicine as directed by your doctor, or follow the directions for use that come with your medicine. The dosage of the drug depends on your condition. Tell your doctor if there is no change or if your condition worsens. Important points to discuss with your healthcare provider are listed below.

    • monitor peak and trough anti-factor Xa levels frequently

    If you use other drugs or supplements at the same time as this drug, the effects of Lovenox Injection may change. Tell your healthcare provider about all medications, vitamins, and supplements you use. Your doctor will be able to make the right plan for taking the drug, which will avoid negative interactions. Lovenox Injectable may interact with the following drugs and products:

    • Acetylsalicylic acid
    • Anticoagulants
    • Dipyridamole
    • Ketorolac tromethamine
    • Salicylates
    • Sulfinpyrazone

      • 900 15

      Hypersensitivity to Lovenox Injectable is a contraindication. In addition, Lovenox Injectable should not be taken if you have the following conditions:

      • active severe bleeding
      • hypersensitivity

        8

      • thrombocytopenia

      Composition and active ingredients

      Lovenox Injectable contains the following active ingredients (salts)

      • Enoxaparin Sodium

      Please note that that this drug is produced with different strengths of intensity for each from the active ingredients listed above.

      Packing Options and Strengths

      Lovenox Injectable is available in the following pack strengths

      Available packages of Lovenox Injectable / Lovenox Injectable: 100MG/ML, 300MG/3ML (100MG/ML)

      FAQ

      • veins and ischemic complications of unstable pain in chest?

        Yes, deep vein thrombosis and ischemic complications of unstable chest pain are among the most common reported uses for Lovenox Injection / Lovenox Injectable. Please do not use Lovenox Injectable for deep vein thrombosis and ischemic complications of unstable chest pain without consulting first with your doctor. Click here and view survey results to find out how others use Lovenox Injection / Lovenox Injectable.

      • Should I use this product on an empty stomach, before or after meals?

        TabletWise.com users have reported taking Lovenox Injectable before meals. However, this information may not apply to your specific situation. Please check with your healthcare provider for a schedule. Click here and view survey results to find out what other users report as timings of using Lovenox Injectable / Lovenox Injectable.

      • Is it safe to drive or operate heavy machinery while using this product?

        If you experience drowsiness, dizziness, hypotension or a headache as side-effects when using Lovenox Injection / Lovenox Injectable medicine then it may not be safe to drive a vehicle or operate heavy machinery. You should stop driving if taking this medicine makes you drowsy, dizzy, or hypotensive. Doctors recommend that you stop drinking alcohol with such drugs, because. alcohol greatly increases the side effects and drowsiness. Please check for these effects on your body when using Lovenox Injectable. Be sure to consult your doctor for advice based on the characteristics of your body and general health.

      • Is this drug (product) addictive or addictive?

        Most drugs are not habit-forming or addictive. In most cases, the state classifies drugs that can be addictive as controlled dispensing drugs. For example, schedule H or X in India and schedule II-V in the USA. Please check the information on the drug packaging to make sure that this drug is not in the controlled category. Also, do not self-medicate or accustom your body to medications without consulting your doctor.

      • Can I stop using this product immediately or do I need to slowly stop using it?

        Some medications need to be stopped gradually due to a rebound effect. Be sure to consult your healthcare provider for advice based on your body, general health, and other medications you may be taking.

      Cite this page

      Page URL

      HTML Link

      Lovenox Injectable

      APA Style Citation
      • Lovenox Injectable jetable in English – Product – TabletWise.com. (n.d.). Retrieved April 14, 2023, from https://www.tabletwise.com/us-ru/lovenox-injectable
      MLA Style Citation
      • “Lovenox Injectable / Lovenox Injectable in English – Product – TabletWise.com” Tabletwise.com . N.p., n.d. Web. 14 Apr. 2023.
      Chicago Style Citation
      • Lovenox Injectable in English – Product – TabletWise.com Tabletwise. Accessed April 14, 2023. https://www.tabletwise.com/us-ru/lovenox-injectable.

      More information about Lovenox Injectable / Lovenox Injectable

      • Uses of
      • Reviews
      • What are the uses of Lovenox Injectable / Lovenox Injectable?
      • What are the side effects of Lovenox Injectable?
      • What other medicines does Lovenox Injectable interact with?
      • When should you not take Lovenox Injectable?
      • What precautions should you take while using Lovenox Injectable?

      Last updated date

      This page was updated on 9/28/2020.

      This page provides information for Lovenox Injectable Product in English .

      Share with friends, get 20% off

      Invite your friends to TabletWise learning marketplace. For each purchase they make, you get 20% off (upto $10) on your next purchase.

      Use of statins, anticoagulants, antiplatelet agents and antiarrhythmic drugs in patients with COVID-19 | Shlyakhto

      1. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS et al. Endothelial cell infection and endothelitis in COVID-19. The Lancet. 2020;395(10234):1417–8. DOI: 10.1016/S0140-6736(20)30937-5

      2. Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19. Journal of Thrombosis and Haemostasis. 2020;jth.14849. [Epub ahead of print]. DOI: 10.1111/jth.14849

      3. Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. JAMA Cardiology. 2020; [Epub ahead of print]. DOI: 10.1001/jamacardio.2020.1286

      4. Hu T, Chen B, Zhou S, Mao J. Simvastatin inhibits inflammatory response in lipopolysaccharide (LPS)-stimulated RAW264.7 macrophages through the microRNA-22/Cyr61 axis. International Journal of Clinical and Experimental Pathology. 2018;11(8):3925–33. PMID: 31949780

      5. Gorabi AM, Kiaie N, Hajighasemi S, Banach M, Penson PE, Jamialahmadi T et al. Statin-Induced Nitric Oxide Signaling: Mechanisms and Therapeutic Implications. Journal of Clinical Medicine. 2019;8(12):2051. DOI: 10.3390/jcm8122051

      6. Kunutsor SK, Seidu S, Khunti K. Statins and primary prevention of venous thromboembolism: a systematic review and meta-analysis. The Lancet Haematology. 2017;4(2):e83–93. DOI: 10.1016/S2352-3026(16)30184-3

      7. Kunutsor SK, Seidu S, Khunti K. Statins and secondary prevention of venous thromboembolism: pooled analysis of published observational cohort studies. European Heart Journal. 2017;38(20):1608–12. DOI: 10.1093/eurheartj/ehx107

      8. Nagashima T, Okazaki H, Yudoh K, Matsuno H, Minota S. Apoptosis of rheumatoid synovial cells by statins through the blocking of protein geranylgeranylation: A potential therapeutic approach to rheumatoid arthritis. Arthritis & Rheumatism. 2006;54(2):579–86. DOI: 10.1002/art.21564

      9. Yuan S. Statins May Decrease the Fatality Rate of Middle East Respiratory Syndrome Infection. mBio. 2015;6(4):e01120. DOI: 10.1128/mBio.01120-15

      10. Fedson DS. Treating influenza with statins and other immunomodulatory agents. antiviral research. 2013;99(3):417–35. DOI: 10.1016/j.antiviral.2013.06.018

      11. Vandermeer ML, Thomas AR, Kamimoto L, Reingold A, Gershman K, Meek J et al. Association Between Use of Statins and Mortality Among Patients Hospitalized With Laboratory-Confirmed Influenza Virus Infections: A Multistate Study. Journal of Infectious Diseases. 2012;205(1):13–9. DOI: 10.1093/infdis/jir695

      12. Massachusetts General Hospital. Hematology Recommendations and Dosing Guidelines during COVID-19. Version 8.0. 4/30/2020. Av. at: https://www.massgeneral.org/assets/MGH/pdf/news/coronavirus/guidance-from-mass-general-hematology.pdf.

      13. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–9. DOI: 10.1001/jama.2020.1585

      14. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiology. 2020;e201017. [Epub ahead of print]. DOI: 10.1001/jamacardio.2020.1017

      15. Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A et al. Clinical Characteristics of Covid-19in New York City. New England Journal of Medicine. 2020;NEJMc2010419. [Epub ahead of print]. DOI: 10.1056/NEJMc2010419

      16. European Society of Cardiology. ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic. Last updated on 21 April 2020. Av. at: https://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-Guidance.

      17. The Liverpool Drug Interaction Group. Liverpool COVID-19 Interactions. Detailed recommendations for interactions with experimental COVID-19therapies. 2020. [Internet] Available at: https://www.covid19-druginteractions.org/

      18. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal. 2016;37(38):2893–962. DOI: 10.1093/eurheartj/ehw210

      19. Xiong T-Y, Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. European Heart Journal. 2020;41(19):1798–800. DOI: 10.1093/eurheartj/ehaa231

      20. Kushakovsky M.S., Grishkin Yu.N. Arrhythmias of the heart. Rhythm and conduction disturbances. Causes, mechanisms, electrocardiographic and electrophysiological diagnostics, clinic, treatment: a guide for physicians. 4th ed., rev. and additional – St. Petersburg: Folio, 2014. -720s. ISBN 978-5-93929-245-0

      21. Heart Rhythm Society. HRS COVID-19 Task Force Update: April 21, 2020. General guidance for QTc monitoring in COVID-19 patients. Av. at: https://www.hrsonline.org/hrs-covid-19-task-force-updateapril-21-2020.

      22. Ministry of Health of the Russian Federation. Temporary guidelines. Prevention, diagnosis and treatment of novel coronavirus infection (COVID-2019). Version 6 (04/28/2020). Available at: https://ctopcoronavirus.rf/ai/doc/194/attach/28042020_mR_COVID-19_v6.pdf

      23. Shlyakhto E.V., Konradi A.O., Arutyunov G.P., Arutyunov A.G. ., Bautin A.E., Boytsov S.A. et al. Guidance for the diagnosis and treatment of diseases of the circulatory system in the context of the COVID-19 pandemic. Russian journal of cardiology. 2020;25(3):129-48. DOI: 10.15829/1560-4071-2020-3-3801

      24. Arutyunov G.P., Tarlovskaya E.I., Koziolova N.A., Boldina M.V., Batyushin M.M., Ametov A. WITH. Agreed position of experts of the Eurasian Association of Physicians on the tactics of managing patients with comorbid pathology infected with SARS-Cov-2. Therapeutic archive. 2020;92(9). (in the press). DOI: 10.26442/00403660.2020.09.000703

      25. Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E et al. COVID-19and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up. Journal of the American College of Cardiology. 2020;S0735109720350087. [Epub ahead of print]. DOI: 10.1016/j.jacc.2020.04.031

      26. Thachil J, Tang N, Gando S, Falanga A, Cattaneo M, Levi M et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. Journal of Thrombosis and Haemostasis. 2020;jth.14810. [Epub ahead of print]. DOI: 10.1111/jth.14810

      27. Arutyunov G.P., Koziolova N.A., Tarlovskaya E.I., Arutyunov A.G., Grigoryeva N.Yu., Dzhunusbekova G.A. Agreed position of experts of the Eurasian Association of Physicians on some new mechanisms of the pathogenesis of COVID19: focus on hemostasis, issues of blood transfusion and the blood gas transport system. Cardiology. 2020;60(5):1-8. DOI: 10.18087/cardio.2020.5.n1132

      28. Cohen AT, Spiro TE, Spyropoulos AC, DeSanctis YH, Homering M, Büller HR et al. D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial. Journal of Thrombosis and Haemostasis. 2014;12(4):479-87. DOI: 10.1111/jth.12515

      29. Gibson C, Spyropoulos A, Cohen A, Hull R, Goldhaber S, Yusen R et al. The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification. TH Open. 2017;1(1):e56–65. DOI: 10.1055/s-0037-1603929

      30. Oudkerk M, Büller HR, Kuijpers D, van Es N, Oudkerk SF, McLoud TC et al. Diagnosis, Prevention, and Treatment of Thromboembolic Complications in COVID-19: Report of the National Institute for Public Health of the Netherlands. radiology. 2020;201629. [Epub ahead of print]. DOI: 10.1148/radiol.2020201629

      31. Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score: Padua Prediction Score. Journal of Thrombosis and Haemostasis. 2010;8(11):2450–7. DOI: 10.1111/j.1538-7836.2010.04044.x

      32. Cohen AT, Spiro TE, Büller HR, Haskell L, Hu D, Hull R et al. Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients. New England Journal of Medicine. 2013;368(6):513–23. DOI: 10.1056/NEJMoa1111096

      33. Goldhaber SZ, Leizorovicz A, Kakkar AK, Haas SK, Merli G, Knabb RM et al. Apixaban versus Enoxaparin for Thromboprophylaxis in Medically Ill Patients. New England Journal of Medicine. 2011;365(23):2167–77. DOI: 10.1056/NEJMoa1110899

      34. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. Journal of Thrombosis and Haemostasis. 2020;18(5):1094–9. DOI: 10.1111/jth.14817

      35. Iba T, Levy JH, Warkentin TE, Thachil J, Poll T, Levi M et al. Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. Journal of Thrombosis and Haemostasis. 2019;17(11):1989–94. DOI: 10.1111/jth.14578

      36. Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA et al. Prevention of VTE in Nonsurgical Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2):e195S-e226S. DOI: 10.1378/chest.11-2296

      37. Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, Nicol P et l. Extended-Duration Venous Thromboembolism Prophylaxis in Acutely Ill Medical Patients With Recently Reduced Mobility: A Randomized Trial. Annals of Internal Medicine. 2010;153(1):8. DOI: 10.7326/0003-4819-153-1-201007060-00004

      38. Cohen AT, Harrington RA, Goldhaber SZ, Hull RD, Wiens BL, Gold A et al. Extended Thromboprophylaxis with Betrixaban in Acutely Ill Medical Patients.